## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.5% in lower entry zone (4.0-10.0%), top 8% cross-sectional ranking. Caution: MRS_5 (-0.7%) diverging from MRS_20, watch for reversal. Outperforming sector by 5.8%. Caution: momentum weakening (-3.5% MRS), overbought RSI (74).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($11.44)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bearish (Bullish: 0, Bearish: 1)

**1. Class Action Lawsuit Filed Against Viatris Inc. (VTRS) - Recover Losses - Contact Levi & Korsinsky Before June 3, 2025**
- Source: WJBF | 20251222T080912 | Bearish | Relevance: 100%
- A class action securities lawsuit has been filed against Viatris Inc. (NASDAQ:VTRS) concerning alleged securities fraud between August 8, 2024, and February 26, 2025. The lawsuit claims Viatris misrepresented the impact of an FDA warning letter regarding its Indore, India facility, leading to a significant stock price drop on February 27, 2025, after disappointing fiscal guidance. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky for information on recovery.

**2. Is Viatris stock outperforming the Dow?**
- Source: MSN | 20251221T150843 | Neutral | Relevance: 100%
- The article asks whether Viatris stock is outperforming the Dow, but the provided content is empty beyond the title. Therefore, no information is available to answer this question.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $15 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 4.9x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.9B |
| Beta | 0.83 |
| 52W Range | $6.85 - $12.68 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 4.9 |
| Current P/E | 5.2 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 9.0% to 5.5% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 92nd percentile. MRS_5 (-0.7%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 6.5% shows strong absolute momentum above own 20MA. Outperforming sector by 5.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 74, risk of mean reversion. Elevated volume (1.8x 20MA), institutional activity likely. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.45% (CS: 92) | Strong |
| RSI_14 | 73.8 | Overbought |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.065x | Above |
| vs SMA50 | 1.116x | Above |
| vs SMA200 | 1.257x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $12.02
- **Stop Loss:** $11.44 (4.8% risk)
- **Target:** $12.89 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 2068
- **Position Value:** $24,857.36
- **Portfolio %:** 24.86%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*